B
Beata Lecka-Czernik
Researcher at University of Toledo
Publications - 74
Citations - 6853
Beata Lecka-Czernik is an academic researcher from University of Toledo. The author has contributed to research in topics: Osteoblast & Bone remodeling. The author has an hindex of 35, co-authored 72 publications receiving 6270 citations. Previous affiliations of Beata Lecka-Czernik include Veterans Health Administration & St. Joseph Hospital.
Papers
More filters
Journal ArticleDOI
Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-γ2 transcription factor and TGF-β/BMP signaling pathways
TL;DR: It is demonstrated that, during aging, the status of mMSC changes with respect to both their intrinsic differentiation potential and production of signaling molecules, which contributes to the formation of a specific marrow microenvironment necessary for maintenance of bone homeostasis.
Journal ArticleDOI
Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2.
Beata Lecka-Czernik,Igor Gubrij,Elena J. Moerman,Oumitana Kajkenova,David A. Lipschitz,David A. Lipschitz,Stavros C. Manolagas,Robert L. Jilka +7 more
TL;DR: It is strongly suggested that PPARγ2 negatively regulates stromal cell plasticity by suppressing Osf2/Cbfa1 and osteoblast‐like biosynthetic activity, while promoting terminal differentiation to adipocytes.
Journal ArticleDOI
Thiazolidinedione use and bone loss in older diabetic adults.
Ann V. Schwartz,Deborah E. Sellmeyer,Eric Vittinghoff,Lisa Palermo,Beata Lecka-Czernik,Kenneth R. Feingold,Elsa S. Strotmeyer,Helaine E. Resnick,Laura D Carbone,Brock A. Beamer,Seok Won Park,Nancy E Lane,Tamara B. Harris,Steven R. Cummings +13 more
TL;DR: These observational results suggest that TZDs may cause bone loss in older women, and these results need to be tested in a randomized trial.
Journal ArticleDOI
Bone Is a Target for the Antidiabetic Compound Rosiglitazone
TL;DR: In vivo data suggest that rosiglitazone therapy may pose a significant risk of adverse skeletal effects in humans.
Journal ArticleDOI
Divergent Effects of Selective Peroxisome Proliferator-Activated Receptor-γ2 Ligands on Adipocyte Versus Osteoblast Differentiation
Beata Lecka-Czernik,Elena J. Moerman,David F. Grant,Jürgen M Lehmann,Stavros C. Manolagas,Robert L. Jilka +5 more
TL;DR: It is shown that the naturally occurring PPARγ ligands 9,10-dihydroxyoctadecenoic acid, and 15-deoxy-Δ12,14-PGJ2, also stimulate adipocytes and inhibit osteoblast differentiation of U-33/γ2 cells.